We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
Read MoreHide Full Article
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on PDL BioPharma, Inc. (PDLI - Free Report) as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for PDLI’s status as a solid momentum stock below:
Short Term Price Change for PDL BioPharma
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of 6.2% compared to an industry average of 0.1%, PDLI is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.
Fiscal Year EPS Estimate Change for PDLI
In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if PDLI is poised to make a run based on fundamentals, or if the company is simply moving on speculation.
Over the past month, the full year earnings estimate for PDLI has risen by 100%. On its own this is impressive, but considers that it also beats the industry average of 0.0% too. The trend is undeniably in PDL BioPharma’s favor right now, and it suggests that the momentum might be long lasting for this stock.
PDLI Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with PDLI as of late too.
Over the past two months, one earnings estimate has gone higher compared to none lower for the full year, while we are also seeing that one estimate has moved upwards with no downward revision for the next year time frame too. These revisions have helped to boost the consensus estimate as two months ago PDLI was expected to post earnings of 19 cents per share for the full year, though today it looks to have EPS of 38 cents for the full year now, representing a solid increase, which is something that should definitely be welcomed news to would-be investors.
Bottom Line
Given these factors, investors shouldn’t be surprised to note that we have PDLI as a security with a Zacks Rank #1 (Strong Buy) and a Momentum Score of ‘A’. You can see the complete list of today’s Zacks #1 Rank stocks here.
So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep PDLI on your short list as this looks be a stock that is very well-positioned to soar in the near term.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on PDL BioPharma, Inc. (PDLI - Free Report) as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for PDLI’s status as a solid momentum stock below:
Short Term Price Change for PDL BioPharma
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of 6.2% compared to an industry average of 0.1%, PDLI is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.
Fiscal Year EPS Estimate Change for PDLI
In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if PDLI is poised to make a run based on fundamentals, or if the company is simply moving on speculation.
Over the past month, the full year earnings estimate for PDLI has risen by 100%. On its own this is impressive, but considers that it also beats the industry average of 0.0% too. The trend is undeniably in PDL BioPharma’s favor right now, and it suggests that the momentum might be long lasting for this stock.
PDLI Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with PDLI as of late too.
PDL BioPharma, Inc. Price and Consensus
PDL BioPharma, Inc. Price and Consensus | PDL BioPharma, Inc. Quote
Over the past two months, one earnings estimate has gone higher compared to none lower for the full year, while we are also seeing that one estimate has moved upwards with no downward revision for the next year time frame too. These revisions have helped to boost the consensus estimate as two months ago PDLI was expected to post earnings of 19 cents per share for the full year, though today it looks to have EPS of 38 cents for the full year now, representing a solid increase, which is something that should definitely be welcomed news to would-be investors.
Bottom Line
Given these factors, investors shouldn’t be surprised to note that we have PDLI as a security with a Zacks Rank #1 (Strong Buy) and a Momentum Score of ‘A’. You can see the complete list of today’s Zacks #1 Rank stocks here.
So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep PDLI on your short list as this looks be a stock that is very well-positioned to soar in the near term.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>